[{"id":"4a225605-ea40-4786-bbe9-47b89ed77c1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05234307","created_at":"2022-02-10T13:52:54.502Z","updated_at":"2024-07-02T16:35:14.388Z","phase":"Phase 1","brief_title":"PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05234307","lead_sponsor":"Dwight Owen","biomarkers":" PD-L1 • ALK • STK11","pipe":"","alterations":" ","tags":["PD-L1 • ALK • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • PBF-1129"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-15"},{"id":"e68d2a21-c443-4058-9176-91b7dbc528d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03274479","created_at":"2021-01-18T16:10:19.023Z","updated_at":"2024-07-02T16:35:20.103Z","phase":"Phase 1","brief_title":"PBF-1129 in Patients With NSCLC","source_id_and_acronym":"NCT03274479","lead_sponsor":"Palobiofarma SL","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ALK mutation • ROS1 mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PBF-1129"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-02-09"}]